Testimonials

AR

Adam Rogers
Hemera Biosciences

The value in this meeting is discussing and sharing results of animal and human data that blocking complement is an effective treatment for ocular diseases.

Meeting with industry peers and exchanging on current and future therapies provides an invaluable opportunity to continue bringing value to patients with complement therapeutics.

Camil Sayegh
UCB Ra Pharma

CS
CL

Cynthia Lemere
Harvard Media School

I look forward to hearing the latest in complement research across many fields and to forming   new collaborations.  I am also interested in learning how complement may be involved in COVID-19 disease progression.

To learn more about the complement system in a spectrum of human diseases.

Edward Patz
Grid Therapeutics

Edward Patz
Francesca Granata

Francesca Granata
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico di Milano

The Value of my contribution to this meeting will be the deepening of the complement system study applied to rare disease. The explanation of our method of work could be able to fit for another disease in order to design a new approach for the complement system assessment.

To provide an opportunity to maximize academic and industry scientific exchanges to  allow novel collaborative efforts

Giulio Pasinetti
Icahn School of Medicine at Mount Sinai

Giulio Pasinetti
Renfeng Guo

Renfeng Guo
InflaRx

This event is a great opportunity to learn other exciting clinical and pre-clinical programs in the complement space.

The Complement-based Drug Discovery Meeting provides a unique opportunity to interact with academic and industry experts who focus on the distinctive challenges of developing treatment for range of diseases driven by pathological activation the complement system.

Sanjay Keswani
Annexon Biosciences

Sanjay Keswani
Sha-Mei Liao

Sha-Mei Liao
Novartis

Exchanging scientific and clinical learnings about complement’s role in health and diseases enabling better treatment options for patients

Interacting with peers and colleagues to drive creative thinking and innovation for our approaches developing therapies for debilitating diseases with unmet medical need.

Stephen Poor
Novartis

SP
Wynne Weston-Davies

Wynne Weston-Davis
Akari Therapeutics

This is a critical and very exciting year for complement medicine. After years of being just an interesting treatment of a few rare diseases, complement is now recognised as a pivotal element of the whole spectrum of immunity, auto-immunity and auto-inflammation. COVID-19 has brought it to the forefront of medical science.